OUR MEDICAL SPECIALISTS  >  DEPARTMENT OF BREAST SURGERY & BREAST CANCER INSTITUTE

Prof. Shao Zhimin, MD, PhD

Director of Breast Cancer Institute · Leading International Breast Cancer Authority  |  Fudan University Shanghai Cancer Center (FUSCC)

Prof. Shao Zhimin, MD, PhD
DIRECTOR OF BREAST CANCER INSTITUTE · LEADING INTERNATIONAL BREAST CANCER AUTHORITY

Prof. Shao Zhimin, MD, PhD

Department of Breast Surgery & Breast Cancer Institute
Fudan University Shanghai Cancer Center (FUSCC)
  • Hospital Affiliation
    Fudan University Shanghai Cancer Center (FUSCC)
  • Clinical Specialty
    Breast Surgical Oncology & Precision Molecular Subtyping
  • Clinical Languages
    English, Mandarin
  • Clinical Experience
    35+ Years
  • Consultation Turnaround
    24–48 Hours Priority Review
Request Specialist Review →
ACCREDITED CHAIR PROFILE & CLINICAL OVERVIEW

Architect of the Fudan Four-Subtype Precision Paradigm in Triple-Negative Breast Cancer

Prof. Shao Zhimin, MD, PhD, is Tenured Professor of Surgical Oncology, Director of the Breast Cancer Institute at Fudan University, and Chair of the Department of Breast Surgery at Fudan University Shanghai Cancer Center (FUSCC). Internationally celebrated as China's foremost breast cancer authority, Prof. Shao has transformed the management of aggressive breast malignancies globally.

Prof. Shao's signature scientific breakthrough—the 'Fudan Four-Subtype Classification' of Triple-Negative Breast Cancer (TNBC)—categorized previously untreatable heterogeneous TNBC into four precision therapeutic subtypes (IM, LAR, MES, BLIS). Leading the landmark FUTURE clinical trial series, his team proved that subtype-tailored targeted combinations dramatically double response rates in metastatic TNBC patients.

Surgically, Prof. Shao leads a department performing over 8,000 breast oncology procedures annually. He pioneered oncoplastic breast-conserving techniques, reverse axillary mapping for lymphedema prevention, and nipple-sparing mastectomy with immediate autologous/implant reconstruction, achieving pristine cosmetic outcomes alongside international 5-year survival rates exceeding 93%.

Primary Appointment Director, Breast Cancer Institute, Fudan University Shanghai Cancer Center
Academic Rank Tenured Professor of Surgical Oncology, Fudan University
National Governance Honorary Chair, Breast Cancer Committee of Chinese Anti-Cancer Association (CACA-CBCS)
International Guidelines Panelist, St. Gallen International Breast Cancer Consensus Conference; Member, ASCO / ESMO
CORE OPERATIVE MASTERY & CLINICAL EXCELLENCE

Procedural Frontiers & Department Innovations

Fudan TNBC Precision Subtyping

Translating multi-omics RNA sequencing into subtype-guided targeted therapies (e.g. anti-androgen for LAR, immunotherapy for IM), transforming incurable TNBC.

Oncoplastic Breast-Conserving Surgery

Mastery of advanced glandular flap repositioning, preserving natural breast contours with zero compromise on microscopically negative surgical margins.

Axillary Reverse Mapping (ARM)

Delineates upper extremity lymph drainage separately from breast drainage, reducing postoperative chronic arm lymphedema rates to below 3%.

Adaptive Neoadjuvant Strategy

Applies targeted immunotherapy and ADC agents before surgery, converting inoperable locally advanced tumors into complete pathologic response (pCR).

ACADEMIC AWARDS & LANDMARK TREATISES

Distinguished National & International Recognition

CANCER CELL
Genomic & Transcriptomic Landscape of Triple-Negative Breast Cancer
The foundational publication defining the Fudan Four-Subtype TNBC framework worldwide.
LANCET ONCOLOGY
Subtyping-Based Targeted Therapy for Refractory Metastatic TNBC
Pivotal FUTURE trial showing superior clinical benefit rate of 52.6% in multi-refractory disease.
CELL RESEARCH
Metabolic Reprogramming & Immune Escape in Breast Cancer
Unveiled metabolic vulnerabilities that enhance response to immune checkpoint inhibition.
NATIONAL AWARD
National Science & Technology Progress Award (2nd Class)
Twice awarded by the State Council for transformative contributions to breast cancer care.

CASE INTAKE & BREAST ONCOLOGY TRIAGE

Request a Breast Oncology Review with Prof. Shao Zhimin, MD, PhD

Submit breast pathology slides/reports, ER/PR/HER2/Ki-67 IHC reports, NGS genetic testing (BRCA1/2), and mammogram/MRI imaging for direct surgical and systemic evaluation by Prof. Shao Zhimin. Our team responds within 24–48 hours.

    Prof. Shao Zhimin, MD, PhD